HC Wainwright Lowers Sol-Gel Technologies (NASDAQ:SLGL) Price Target to $6.00

Sol-Gel Technologies (NASDAQ:SLGL) had its price objective reduced by HC Wainwright from $9.00 to $6.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q1 2024 earnings at ($0.16) EPS, Q2 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.60) EPS.

Sol-Gel Technologies Trading Down 1.2 %

Shares of NASDAQ SLGL opened at $0.79 on Monday. Sol-Gel Technologies has a one year low of $0.63 and a one year high of $4.05. The business has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $1.10. The firm has a market capitalization of $22.01 million, a PE ratio of -0.95 and a beta of 1.38.

Sol-Gel Technologies (NASDAQ:SLGL) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sol-Gel Technologies had a negative return on equity of 52.73% and a negative net margin of 1,329.13%. The company had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.27 million. Research analysts anticipate that Sol-Gel Technologies will post -0.67 EPS for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.